Impact of Erythromycin and Rifampicin on Liver Function Test
Author Information
Author(s): Bhise Satish Balkrishna, Dias Remeth Jacky
Primary Institution: Govt. College of Pharmacy, Vidyanagar, Karad, India
Hypothesis
The study aims to evaluate the effect of CYP3A4 modifiers erythromycin and rifampicin on the MEGX test.
Conclusion
The MEGX test is not affected by the concomitant administration of rifampicin and erythromycin.
Supporting Evidence
- Rifampicin increased MEGX concentrations, but the change was not statistically significant.
- Erythromycin decreased MEGX concentrations, but this effect was also not statistically significant.
- The study included only healthy male volunteers, which may not represent the general population.
Takeaway
This study looked at how two medications affect a liver test, and it found that they don't change the test results.
Methodology
Twenty healthy male volunteers were given lidocaine, followed by either erythromycin or rifampicin for six days, and MEGX concentrations were measured.
Limitations
The study only included healthy male volunteers, which may limit the generalizability of the results.
Participant Demographics
Twenty healthy male volunteers with normal laboratory tests.
Statistical Information
P-Value
P = 0.085 for MEGX30 and P = 0.051 for MEGX60 with rifampicin; P = 0.128 for MEGX30 and P = 0.159 for MEGX60 with erythromycin.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website